US sPMA for DJO's bone products:
This article was originally published in Clinica
DJO has received FDA approval for a PMA supplement covering several new features built into its combined magnetic field (CMF) OL1000 and SpinaLogic bone growth stimulation product lines. The devices employ the San Diego, California firm's CMF technology, which it claims is the only waveform clinically proven to stimulate bone growth. The technology is indicated for use in aiding the healing of fractures in both long bone and primary lumbar spine applications. The new CMF OL1000 and SpinaLogic products are slated for launch in international markets in September.
You may also be interested in...
The biopharma industry has struggled to recruit patients into clinical trials that adequately reflect the diverse patient populations they hope to reach with new products. Failure to improve minority subgroup participation now will cost trial sponsors later.
A flurry of US biosimilar launches over the past few months has opened several molecules to true, multi-source competition, with a range of pricing strategies seen from competitors. However, some brands that already face biosimilar competition elsewhere in the world are still poised to enjoy a significant period of exclusivity in the US, such as AbbVie’s Humira.
It is the question that continues to exercise the minds of management boards in the medtech industry even as digital health care tools become increasingly ingrained in commercial R&D and operations – and in patient treatment pathways.